Mind Medicine (MindMed) (MNMD) Set to Announce Earnings on Tuesday

Mind Medicine (MindMed) (NASDAQ:MNMD) is set to post its quarterly earnings results before the market opens on Tuesday, August 13th. Analysts expect Mind Medicine (MindMed) to post earnings of ($0.30) per share for the quarter.

Mind Medicine (MindMed) (NASDAQ:MNMD) last posted its earnings results on Wednesday, May 8th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.06. On average, analysts expect Mind Medicine (MindMed) to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mind Medicine (MindMed) Price Performance

Mind Medicine (MindMed) stock opened at $8.24 on Wednesday. Mind Medicine has a 52-week low of $2.41 and a 52-week high of $12.22. The company has a quick ratio of 3.91, a current ratio of 3.91 and a debt-to-equity ratio of 0.07. The firm’s fifty day moving average is $7.86 and its 200 day moving average is $7.70. The company has a market cap of $592.23 million, a price-to-earnings ratio of -2.59 and a beta of 2.58.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Mind Medicine (MindMed) in a research report on Wednesday, July 31st. Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 price objective (down from $29.00) on shares of Mind Medicine (MindMed) in a research note on Monday, May 13th. Baird R W upgraded Mind Medicine (MindMed) to a “strong-buy” rating in a report on Wednesday, May 29th. Roth Mkm initiated coverage on Mind Medicine (MindMed) in a report on Wednesday, July 24th. They set a “buy” rating and a $36.00 price target on the stock. Finally, Robert W. Baird assumed coverage on Mind Medicine (MindMed) in a research report on Tuesday, May 28th. They issued an “outperform” rating and a $27.00 price target for the company. Nine analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $22.00.

Insider Buying and Selling at Mind Medicine (MindMed)

In other news, CEO Robert Barrow sold 15,659 shares of Mind Medicine (MindMed) stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $7.22, for a total transaction of $113,057.98. Following the completion of the sale, the chief executive officer now directly owns 564,543 shares in the company, valued at $4,076,000.46. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Mind Medicine (MindMed) news, insider Dan Karlin sold 6,925 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $7.22, for a total value of $49,998.50. Following the completion of the sale, the insider now directly owns 351,527 shares in the company, valued at approximately $2,538,024.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert Barrow sold 15,659 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $7.22, for a total value of $113,057.98. Following the transaction, the chief executive officer now directly owns 564,543 shares in the company, valued at approximately $4,076,000.46. The disclosure for this sale can be found here. 2.26% of the stock is currently owned by corporate insiders.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.